Cargando…

Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort

BACKGROUND: Topoisomerase I (Top1) is the target of Top1 inhibitor chemotherapy. The TOP1 gene, located at 20q12-q13.1, is frequently detected at elevated copy numbers in colorectal cancer (CRC). The present study explores the mechanism, frequency and prognostic impact of TOP1 gene aberrations in st...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, David Hersi, Christensen, Ib Jarle, Jensen, Niels Frank, Markussen, Bo, Rømer, Maria Unni, Nygård, Sune Boris, Müller, Sven, Nielsen, Hans Jørgen, Brünner, Nils, Nielsen, Kirsten Vang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618421/
https://www.ncbi.nlm.nih.gov/pubmed/23577133
http://dx.doi.org/10.1371/journal.pone.0060613
_version_ 1782265417822109696
author Smith, David Hersi
Christensen, Ib Jarle
Jensen, Niels Frank
Markussen, Bo
Rømer, Maria Unni
Nygård, Sune Boris
Müller, Sven
Nielsen, Hans Jørgen
Brünner, Nils
Nielsen, Kirsten Vang
author_facet Smith, David Hersi
Christensen, Ib Jarle
Jensen, Niels Frank
Markussen, Bo
Rømer, Maria Unni
Nygård, Sune Boris
Müller, Sven
Nielsen, Hans Jørgen
Brünner, Nils
Nielsen, Kirsten Vang
author_sort Smith, David Hersi
collection PubMed
description BACKGROUND: Topoisomerase I (Top1) is the target of Top1 inhibitor chemotherapy. The TOP1 gene, located at 20q12-q13.1, is frequently detected at elevated copy numbers in colorectal cancer (CRC). The present study explores the mechanism, frequency and prognostic impact of TOP1 gene aberrations in stage III CRC and how these can be detected by fluorescent in situ hybridization (FISH). METHODS: Nine CRC cell line metaphase spreads were analyzed by FISH with a TOP1 probe in combination with a reference probe covering either the centromeric region of chromosome 20 (CEN-20) or chromosome 2 (CEN-2). Tissue sections from 154 chemonaive stage III CRC patients, previously studied with TOP1/CEN-20, were analyzed with TOP1/CEN-2. Relationships between biomarker status and overall survival (OS), time to recurrence (TTR) in CRC and time to local recurrence (LR; rectal cancer only) were determined. RESULTS: TOP1 aberrations were observed in four cell line metaphases. In all cell lines CEN-2 was found to reflect chromosomal ploidy levels and therefore the TOP1/CEN-2 probe combination was selected to identify TOP1 gene gains (TOP1/CEN-2≥1.5). One hundred and three patients (68.2%) had TOP1 gain, of which 15 patients (14.6%) harbored an amplification (TOP1/CEN-20≥2.0). TOP1 gene gain did not have any association with clinical endpoints, whereas TOP1 amplification showed a non-significant trend towards longer TTR (multivariate HR: 0.50, p = 0.08). Once amplified cases were segregated from other cases of gene gain, non-amplified gene increases (TOP1/CEN-2≥1.5 and TOP1/CEN-20<2.0) showed a trend towards shorter TTR (univariate HR: 1.57, p = 0.07). CONCLUSIONS: TOP1 gene copy number increase occurs frequently in stage III CRC in a mechanism that often includes CEN-20. Using CEN-2 as a measurement for tumor ploidy levels, we were able to discriminate between different mechanisms of gene gain, which appeared to differ in prognostic impact. TOP1 FISH guidelines have been updated.
format Online
Article
Text
id pubmed-3618421
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36184212013-04-10 Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort Smith, David Hersi Christensen, Ib Jarle Jensen, Niels Frank Markussen, Bo Rømer, Maria Unni Nygård, Sune Boris Müller, Sven Nielsen, Hans Jørgen Brünner, Nils Nielsen, Kirsten Vang PLoS One Research Article BACKGROUND: Topoisomerase I (Top1) is the target of Top1 inhibitor chemotherapy. The TOP1 gene, located at 20q12-q13.1, is frequently detected at elevated copy numbers in colorectal cancer (CRC). The present study explores the mechanism, frequency and prognostic impact of TOP1 gene aberrations in stage III CRC and how these can be detected by fluorescent in situ hybridization (FISH). METHODS: Nine CRC cell line metaphase spreads were analyzed by FISH with a TOP1 probe in combination with a reference probe covering either the centromeric region of chromosome 20 (CEN-20) or chromosome 2 (CEN-2). Tissue sections from 154 chemonaive stage III CRC patients, previously studied with TOP1/CEN-20, were analyzed with TOP1/CEN-2. Relationships between biomarker status and overall survival (OS), time to recurrence (TTR) in CRC and time to local recurrence (LR; rectal cancer only) were determined. RESULTS: TOP1 aberrations were observed in four cell line metaphases. In all cell lines CEN-2 was found to reflect chromosomal ploidy levels and therefore the TOP1/CEN-2 probe combination was selected to identify TOP1 gene gains (TOP1/CEN-2≥1.5). One hundred and three patients (68.2%) had TOP1 gain, of which 15 patients (14.6%) harbored an amplification (TOP1/CEN-20≥2.0). TOP1 gene gain did not have any association with clinical endpoints, whereas TOP1 amplification showed a non-significant trend towards longer TTR (multivariate HR: 0.50, p = 0.08). Once amplified cases were segregated from other cases of gene gain, non-amplified gene increases (TOP1/CEN-2≥1.5 and TOP1/CEN-20<2.0) showed a trend towards shorter TTR (univariate HR: 1.57, p = 0.07). CONCLUSIONS: TOP1 gene copy number increase occurs frequently in stage III CRC in a mechanism that often includes CEN-20. Using CEN-2 as a measurement for tumor ploidy levels, we were able to discriminate between different mechanisms of gene gain, which appeared to differ in prognostic impact. TOP1 FISH guidelines have been updated. Public Library of Science 2013-04-05 /pmc/articles/PMC3618421/ /pubmed/23577133 http://dx.doi.org/10.1371/journal.pone.0060613 Text en © 2013 Smith et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Smith, David Hersi
Christensen, Ib Jarle
Jensen, Niels Frank
Markussen, Bo
Rømer, Maria Unni
Nygård, Sune Boris
Müller, Sven
Nielsen, Hans Jørgen
Brünner, Nils
Nielsen, Kirsten Vang
Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort
title Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort
title_full Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort
title_fullStr Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort
title_full_unstemmed Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort
title_short Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort
title_sort mechanisms of topoisomerase i (top1) gene copy number increase in a stage iii colorectal cancer patient cohort
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618421/
https://www.ncbi.nlm.nih.gov/pubmed/23577133
http://dx.doi.org/10.1371/journal.pone.0060613
work_keys_str_mv AT smithdavidhersi mechanismsoftopoisomeraseitop1genecopynumberincreaseinastageiiicolorectalcancerpatientcohort
AT christensenibjarle mechanismsoftopoisomeraseitop1genecopynumberincreaseinastageiiicolorectalcancerpatientcohort
AT jensennielsfrank mechanismsoftopoisomeraseitop1genecopynumberincreaseinastageiiicolorectalcancerpatientcohort
AT markussenbo mechanismsoftopoisomeraseitop1genecopynumberincreaseinastageiiicolorectalcancerpatientcohort
AT rømermariaunni mechanismsoftopoisomeraseitop1genecopynumberincreaseinastageiiicolorectalcancerpatientcohort
AT nygardsuneboris mechanismsoftopoisomeraseitop1genecopynumberincreaseinastageiiicolorectalcancerpatientcohort
AT mullersven mechanismsoftopoisomeraseitop1genecopynumberincreaseinastageiiicolorectalcancerpatientcohort
AT nielsenhansjørgen mechanismsoftopoisomeraseitop1genecopynumberincreaseinastageiiicolorectalcancerpatientcohort
AT brunnernils mechanismsoftopoisomeraseitop1genecopynumberincreaseinastageiiicolorectalcancerpatientcohort
AT nielsenkirstenvang mechanismsoftopoisomeraseitop1genecopynumberincreaseinastageiiicolorectalcancerpatientcohort